Innovation et accès : fission ou fusion ? Entretien avec Tim Wilsdon, Vice-président de CRA 14/06/2016 by William New, Intellectual Property Watch Leave a Comment Dans le sillage du Groupe de Haut Niveau des Nations Unies sur l’accès aux médicaments, cette série d’articles sponsorisés convie des experts à donner leur point de vue sur les politiques les mieux à même de favoriser l’élaboration de solutions aux plus importants enjeux sociétaux ; ils nous expliquent aussi comment un cadre réglementaire favorable, y […]
Alongside UN Commitments To End AIDS, Event On Access Brings Tears, Vision 13/06/2016 by William New, Intellectual Property Watch 1 Comment NEW YORK — Last week, United Nations members agreed on a political declaration on ending AIDS by 2030, with some new and old commitments. Alongside the 8-10 June High-Level Meeting on Ending AIDS, a side event looked at issues of access and got into intellectual property rights issues.
New Ideas Coming For WTO TRIPS Council; But Also Old Debate Over EU Drug Seizures 09/06/2016 by Catherine Saez, Intellectual Property Watch Leave a Comment The European Union presenting its new Trademark Directive during this week’s meeting of the World Trade Organization intellectual property council heard concerns of possible seizures of generic medicines transiting through Europe. Meanwhile, the new Council chair’s attempts at revitalising discussions between member states received general approval. And a new agenda item on e-commerce was launched.
Antibiotic Resistance Is “Already Here” And Pipeline Is Dry, UK Health Minister Tells UN 08/06/2016 by William New, Intellectual Property Watch 2 Comments NEW YORK — An estimated one million people may already die each year because they are resistant to all known antibiotics, and the number could reach 10 million per year and devastate the world economy by 2050 unless key steps are taken, experts from the United Kingdom and South Africa told a press briefing on antimicrobial resistance at United Nations headquarters today.
Innovación y acceso: ¿fisión o fusión? Entrevista a la Dra. Kristina M. Lybecker, profesora asociada de Economía del Colorado College 07/06/2016 by Guest contributor for Intellectual Property Watch Leave a Comment Tomando como referencia el trabajo del Grupo de Alto Nivel de las Naciones Unidas sobre el Acceso a los Medicamentos, esta serie de artículos patrocinados invita a expertos en la materia a expresar sus puntos de vista sobre las políticas que respaldan con mayor eficacia la formulación de soluciones que respondan a los principales desafíos de las sociedades, y sobre cómo los entornos propicios para la implantación de políticas, incluidas las relativas a los sistemas de propiedad intelectual, influyen en el desarrollo y el caudal de nuevas tecnologías y servicios en diferentes sectores, campos tecnológicos y territorios. Las opiniones expresadas en los artículos son las de los autores. A continuación se presenta una entrevista a la Dra. Kristina M. Lybecker, profesora asociada de Economía del Colorado College, en Colorado Springs.
Innovación y acceso: ¿Fisión o fusión? Entrevista a Tim Wilsdon, vicepresidente de CRA 07/06/2016 by Guest contributor for Intellectual Property Watch Leave a Comment Tomando como referencia el trabajo del Grupo de Alto Nivel de las Naciones Unidas sobre el Acceso a los Medicamentos, esta serie de artículos patrocinados invita a expertos en la materia a expresar sus puntos de vista sobre las políticas que respaldan con mayor eficacia la formulación de soluciones que respondan a los principales desafíos de las sociedades, y sobre cómo los entornos propicios para la implantación de políticas, incluidas las relativas a los sistemas de propiedad intelectual, influyen en el desarrollo y el caudal de nuevas tecnologías y servicios en diferentes sectores, campos tecnológicos y territorios. Las opiniones expresadas en los artículos son las de los autores. A continuación, presentamos la entrevista a Tim Wilsdon, vicepresidente de CRA.
Q&A With Erich Spangenberg On Patents And Drug Prices 03/06/2016 by Intellectual Property Watch 1 Comment Prices for drugs have long been a problem for developing countries but now have become out of reach for many in developed countries, sparking policy debates and efforts to address it. One of the top figures in the patent monetization business, industry maverick Erich Spangenberg offers a lively opinion on the underlying problem and how to fix it. To start? Stop granting patent extensions for minor changes.
Innovation And Access: Fission Or Fusion? Interview With Dr. Kristina M. Lybecker, Associate Professor Of Economics At Colorado College 02/06/2016 by Guest contributor for Intellectual Property Watch 1 Comment In the light of the UN High-Level Panel on Access to Medicines, this series of sponsored articles challenges experts to give their views on the policies that best support the development of solutions to societies’ greatest challenges and how enabling policy environments, including IP systems, influence the development and flow of new technologies and services in different sectors, fields of technology, and jurisdictions. The views expressed in the articles are those of the authors. Below is an interview with Dr. Kristina M. Lybecker, Associate Professor of Economics at Colorado College in Colorado Springs (US).
WHO-Led Study: Hepatitis C Treatment Unaffordable Globally, Threatens Health Systems 01/06/2016 by Catherine Saez, Intellectual Property Watch Leave a Comment According to a new study by experts at the World Health Organization, prices of hepatitis C treatments are unaffordable globally and put a major strain on national health systems. Hepatitis C can cause liver cirrhosis and cancer, and with an estimated 80 million people affected in the world, if untreated, the sickness could lead to 700,000 deaths per year worldwide, the study said, suggesting that governments and industry stakeholders should develop and implement fair pricing frameworks.
WHO’s Kieny: R&D Resolution ‘An Advance That Shows Strong Recommitment’ 31/05/2016 by William New, Intellectual Property Watch Leave a Comment World Health Organization members sent a clear signal at the annual Assembly last week when they committed to step up efforts to find ways to fund research into diseases that results in affordable products, according to the top WHO official working on these issues.